A recent study reported that the combination of zoledronic acid and thymosin α1 [85] successfully treated non-immunoreactive patients with advanced or metastatic prostate cancer (PCa) by blocking MyD88/NF-κB signaling in PCa cells. This evidence concerns the gene MYD88 and posterior cortical atrophy.